首波新冠机械通气患者真菌感染:法国多中心MYCOVID研究
该研究为法国18个ICU开展的多中心观察性队列研究,纳入565例RT-PCR确诊SARS-CoV-2感染并因ARDS接受机械通气的成人患者,其中509例至少采集3次微生物筛查样本者纳入分析。结果显示25%(128例)发生确诊/临床诊断或可能真菌感染,15%(76例)符合确诊/临床诊断CAPA标准。多因素分析显示年龄>62岁、接受地塞米松联合抗IL-6治疗及机械通气>14天与确诊/临床诊断CAPA独立相关;确诊/临床诊断CAPA与ICU死亡独立相关(HR 1.45)。确诊/临床诊断CAPA组ICU死亡率61.8%,显著高于无CAPA组的32.1%(p<0.0001)。作者认为需对重症新冠患者主动监测真菌病原体。
要点
- 509例机械通气新冠患者中76例(15%)符合确诊/临床诊断CAPA,128例(25%)发生确诊/临床诊断或可能真菌感染。
- 年龄>62岁(OR 2.34)、地塞米松联合抗IL-6(OR 2.71)、机械通气>14天(OR 2.16)与确诊/临床诊断CAPA独立相关。
- 确诊/临床诊断CAPA组ICU死亡率61.8%(95%CI 50.0-72.8),无CAPA组32.1%(95%CI 27.7-36.7),p<0.0001。
- 确诊/临床诊断CAPA与ICU死亡独立相关(HR 1.45,95%CI 1.03-2.03,p=0.033),年龄>62岁(HR 1.71)和实体器官移植(HR 2.46)亦为独立因素。
- 32例(6%)发生念珠菌血症,6例(1%)侵袭性毛霉病,1例(<1%)侵袭性镰刀菌病。
适用人群与场景
- 法国18个ICU收治的成人(≥18岁)RT-PCR确诊SARS-CoV-2感染、因急性呼吸窘迫综合征需要机械通气的患者。
- 纳入分析人群为ICU住院期间至少采集3次微生物筛查样本的509例患者(平均年龄59.4岁,标准差12.5;男性400例,79%)。
- 研究期间为2020年2月29日至7月9日。
诊断标准与关键阈值
- 确诊或临床诊断(proven or probable)COVID-19相关肺曲霉病(CAPA)按ECMM/ISHAM最新定义分类。
- 真菌感染分类包括确诊/临床诊断或可能(proven/probable or possible)真菌感染。
处置流程与药物剂量
- 机械通气期间每周系统筛查呼吸道真菌微生物一次或两次,持续至ICU出院。
红旗征与不能漏的情况
- 确诊/临床诊断CAPA患者ICU死亡率高达61.8%(95%CI 50.0-72.8),显著高于无CAPA患者的32.1%(95%CI 27.7-36.7),p<0.0001。
研究设计与关键结果
- 研究类型:法国国家多中心观察性队列研究,18个ICU,回顾性和前瞻性纳入565例机械通气新冠患者,509例至少3次筛查样本者纳入分析。
- 主要终点:128例(25%)发生138次确诊/临床诊断或可能真菌感染;76例(15%)符合确诊/临床诊断CAPA。
- 确诊/临床诊断CAPA独立危险因素:年龄>62岁(OR 2.34,95%CI 1.39-3.92,p=0.0013)、地塞米松联合抗IL-6治疗(OR 2.71,95%CI 1.12-6.56,p=0.027)、机械通气>14天(OR 2.16,95%CI 1.14-4.09,p=0.019)。
- 其他确诊/临床诊断真菌感染:38例(7%)发生一种或以上其他确诊/临床诊断真菌感染,其中念珠菌血症32例(6%)、侵袭性毛霉病6例(1%)、侵袭性镰刀菌病1例(<1%)。
- 509例患者死亡多因素分析(校正念珠菌血症):年龄>62岁(HR 1.71,95%CI 1.26-2.32,p=0.0005)、实体器官移植(HR 2.46,95%CI 1.53-3.95,p=0.0002)、确诊/临床诊断CAPA(HR 1.45,95%CI 1.03-2.03,p=0.033)。
- ICU出院时生存曲线显示,确诊/临床诊断CAPA组ICU总死亡率61.8%(95%CI 50.0-72.8)vs 无CAPA组32.1%(95%CI 27.7-36.7),p<0.0001。
证据类型、等级与局限
- 证据类型:多中心观察性队列研究(回顾性和前瞻性纳入)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,研究结果显示机械通气新冠患者中侵袭性肺曲霉病和念珠菌血症患病率高、确诊/临床诊断CAPA相关死亡率高,这些发现强调需要对重症COVID-19患者进行真菌病原体的主动监测。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Patients with severe COVID-19 have emerged as a population at high risk of invasive fungal infections (IFIs). However, to our knowledge, the prevalence of IFIs has not yet been assessed in large populations of mechanically ventilated patients. We aimed to identify the prevalence, risk factors, and mortality associated with IFIs in mechanically ventilated patients with COVID-19 under intensive care.
METHODS: We performed a national, multicentre, observational cohort study in 18 French intensive care units (ICUs). We retrospectively and prospectively enrolled adult patients (aged ≥18 years) with RT-PCR-confirmed SARS-CoV-2 infection and requiring mechanical ventilation for acute respiratory distress syndrome, with all demographic and clinical and biological follow-up data anonymised and collected from electronic case report forms. Patients were systematically screened for respiratory fungal microorganisms once or twice a week during the period of mechanical ventilation up to ICU discharge. The primary outcome was the prevalence of IFIs in all eligible participants with a minimum of three microbiological samples screened during ICU admission, with proven or probable (pr/pb) COVID-19-associated pulmonary aspergillosis (CAPA) classified according to the recent ECMM/ISHAM definitions. Secondary outcomes were risk factors of pr/pb CAPA, ICU mortality between the pr/pb CAPA and non-pr/pb CAPA groups, and associations of pr/pb CAPA and related variables with ICU mortality, identified by regression models. The MYCOVID study is registered with ClinicalTrials.gov, NCT04368221.
FINDINGS: Between Feb 29 and July 9, 2020, we enrolled 565 mechanically ventilated patients with COVID-19. 509 patients with at least three screening samples were analysed (mean age 59·4 years [SD 12·5], 400 [79%] men). 128 (25%) patients had 138 episodes of pr/pb or possible IFIs. 76 (15%) patients fulfilled the criteria for pr/pb CAPA. According to multivariate analysis, age older than 62 years (odds ratio [OR] 2·34 [95% CI 1·39-3·92], p=0·0013), treatment with dexamethasone and anti-IL-6 (OR 2·71 [1·12-6·56], p=0·027), and long duration of mechanical ventilation (>14 days; OR 2·16 [1·14-4·09], p=0·019) were independently associated with pr/pb CAPA. 38 (7%) patients had one or more other pr/pb IFIs: 32 (6%) had candidaemia, six (1%) had invasive mucormycosis, and one (<1%) had invasive fusariosis. Multivariate analysis of associations with death, adjusted for candidaemia, for the 509 patients identified three significant factors: age older than 62 years (hazard ratio [HR] 1·71 [95% CI 1·26-2·32], p=0·0005), solid organ transplantation (HR 2·46 [1·53-3·95], p=0·0002), and pr/pb CAPA (HR 1·45 [95% CI 1·03-2·03], p=0·033). At time of ICU discharge, survival curves showed that overall ICU mortality was significantly higher in patients with pr/pb CAPA than in those without, at 61·8% (95% CI 50·0-72·8) versus 32·1% (27·7-36·7; p<0·0001).
INTERPRETATION: This study shows the high prevalence of invasive pulmonary aspergillosis and candidaemia and high mortality associated with pr/pb CAPA in mechanically ventilated patients with COVID-19. These findings highlight the need for active surveillance of fungal pathogens in patients with severe COVID-19.
参考来源
- Gangneux JP, Dannaoui E, Fekkar A, et al. Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study. Lancet Respir Med. 2021. PMID: 34843666. doi:10.1016/S2213-2600(21)00442-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。